Study of sacituzumab govitecan with atropine for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding atropine to the chemotherapy drug sacituzumab govitecan can reduce side effects and improve tolerability in people with advanced triple-negative or hormone receptor-positive/HER2-negative breast cancer. It is for patients whose cancer has spread and cannot be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced breast cancer that cannot be surgically removed and has spread to other parts of the body.
- You must have triple-negative breast cancer OR hormone receptor-positive/HER2-negative breast cancer.
- For hormone receptor-positive/HER2-negative cancer, you must have tried at least one previous hormone therapy and a CDK4/6 inhibitor, and the cancer must have progressed after these treatments.
- You must have tried no more than two prior chemotherapy regimens for advanced disease.
- You must be willing to provide a tumor sample and blood/stool samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This trial tests a new drug, Sacituzumab Govitecan, for people with advanced triple-negative breast cancer that hasn't been treated yet. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This trial tests a new drug called sacituzumab govitecan (a targeted chemotherapy) combined with hormone therapy for people whose HR-positive, HER2-negative metastatic breast cancer has worsened after treatment with a CDK4/6 inhibitor. The goal is to see if this combination can help control the cancer when standard options are limited.
This trial tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer. It aims to see if this new approach is safer and more effective.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.